

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1617srh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:35:39 ON 17 MAR 2004

=> eg

EG IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (>).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:35:44 ON 17 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAR 2004 HIGHEST RN 663883-43-0
DICTIONARY FILE UPDATES: 16 MAR 2004 HIGHEST RN 663883-43-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\09-535951 progestin analog.str



chain nodes :

18 19 20 21 22 23 25 27 28

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

2-22 5-18 13-19 15-20 15-28 16-25 20-21 20-23 21-27

ring bonds :

```

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13
13-14 13-15 14-17 15-16 16-17
exact/norm bonds :
1-2 1-6 2-3 2-22 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-14 9-10 11-12
12-13 13-14 13-15 14-17 15-16 15-28 16-17 16-25 20-23 21-27
exact bonds :
5-18 13-19 15-20 20-21

```

G1:H,CH3

G2:H,OH

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS 27:CLASS 28:CLASS


```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 H,Me

G2 H,OH

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 13:36:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3046 TO ITERATE

32.8% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**


PROJECTED ITERATIONS: 57611 TO 64229
PROJECTED ANSWERS: 6500 TO 8850

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Pregn-4-ene-3,20-dione, 11-hydroxy-2 α -methyl- (7CI)
MF C22 H32 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):

=> s 11 exa

STRUCTURES CONTAINING VARIABLE NODES NOT VALID IN EXACT OR FAMILY SEARCH
You have requested a full structure (EXA or FAM) search on a
structure containing one of the special variable-atom symbols
A, M, Q, or X, or a variable group G. Only bond variability
is allowed in structures for EXA or FAM searches. Variable
nodes are never permitted.

=> fil medl hcpl biosis uspatf

COST IN U. S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0 84	1 05

FILE : MEDLINE : ENTERED AT 13:37:03 ON 17 MAR 2004

FILE 'HCAPLUS' ENTERED AT 13:37:03 ON 17 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:37:03 ON 17 MAR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'USPATFULL' ENTERED AT 13:37:03 ON 17 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 12
L3 67 L2

=> S atheroscler?
L4 174783 ATHEROSCLER?

=> s 13 and 14

=> d

L5 ANSWER 1 OF 1 USPATFULL on STN
AN 90:63257 USPATFULL
TI 11a-hydroxy steroid diester
IN Braughler, John M., Portage, MI, United States
Hall, Edward D., Portage, MI, United States
Wierenga, Wendell, Kalamazoo, MI, United States
McCall, John M., Kalamazoo, MI, United States
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 4948533 19900814
AI US 1989-312337 19890216 (7)
RLI Continuation of Ser. No. US 1986-912677, filed on 25 Sep 1986, now abandoned which is a continuation of Ser. No. US 1985-701601, filed on 14 Feb 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-594096, filed on 28 Mar 1984, now abandoned
DT Utility
FS Granted
LN.CNT 2280
INCL INCLM: 552/576.000
INCLS: 552/602.000; 552/566.000; 552/577.000; 552/575.000; 552/572.000;
552/595.000; 552/594.000; 514/179.000; 514/181.000; 540/111.000;
540/113.000; 540/114.000; 540/120.000; 540/088.000; 540/089.000;
540/010.000; 540/033.000
NCL NCLM: 552/576.000
NCLS: 514/179.000; 514/181.000; 540/010.000; 540/033.000; 540/088.000;
540/089.000; 540/111.000; 540/113.000; 540/114.000; 540/120.000;
552/566.000; 552/572.000; 552/575.000; 552/577.000; 552/594.000;
552/595.000; 552/602.000
IC [5]
ICM: A61K031-56
ICS: A61K031-57; C07J005-00
EXF 260/397.45; 260/397.47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs hitstr

L5 ANSWER 1 OF 1 USPATFULL on STN
ACCESSION NUMBER: 90:63257 USPATFULL
TITLE: 11a-hydroxy steroid diester
INVENTOR(S): Braughler, John M., Portage, MI, United States
Hall, Edward D., Portage, MI, United States
Wierenga, Wendell, Kalamazoo, MI, United States
McCall, John M., Kalamazoo, MI, United States
PATENT ASSIGNEE(S): The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4948533		19900814
APPLICATION INFO.:	US 1989-312337		19890216 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1986-912677, filed on 25 Sep 1986, now abandoned which is a continuation of Ser. No. US 1985-701601, filed on 14 Feb 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-594096, filed on 28 Mar 1984, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Higel, Floyd D.		
LEGAL REPRESENTATIVE:	Stein, Bruce, Newton, Ruth H.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2280		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to 21-(3-carboxy-1-oxopropoxy)-
-17 α -hydroxy-11 α -(3,3-dimethyl-1-oxobutoxy)pregna-1,4-diene-
3,20 dione and pharmaceutically acceptable salts thereof which are
useful steroid prodrugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 103227-86-7P

(preparation and esterification of, by succinic anhydride)

RN 103227-86-7 USPATFULL

CN Pregn-4-ene-3,20-dione, 17,21-dihydroxy-11-(1-oxopropoxy)-, (11 α) -
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d kwic

L5 ANSWER 1 OF 1 USPATFULL on STN

SUMM . . . in cancer as well as other disorders or physiological phenomenon dependent on angiogenesis such as embryo implantation (antifertility), arthritis, and atherosclerosis is exhibited with these compounds coadministered with oral heparin or systemic heparin fragments (see J. Folkman, et al., Science 32, . . .

IT 7110-57-8P 15151-39-0P 93269-35-3P 103227-70-9P 103227-80-1P
103227-86-7P 103227-90-3P 103227-93-6P 103227-97-0P
103228-02-0P 103228-06-4P 103228-09-7P 103228-13-3P 103228-23-5P
103228-33-7P 103228-39-3P 103228-42-8P 103228-45-1P 103257-92-7P
105500-05-8P

(preparation and esterification of, by succinic anhydride)

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.20

15.25

FILE 'REGISTRY' ENTERED AT 13:38:27 ON 17 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAR 2004 HIGHEST RN 663883-43-0

DICTIONARY FILE UPDATES: 16 MAR 2004 HIGHEST RN 663883-43-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s 17-hydroxyprogesterone/cn
L6 1 17-HYDROXYPROGESTERONE/CN

=> d

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 68-96-2 REGISTRY
CN Pregn-4-ene-3,20-dione, 17-hydroxy- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Δ^4 -Pregn-17 α -ol-3,20-dione
CN 17-Hydroxypregn-4-ene-3,20-dione
CN **17-Hydroxyprogesterone**
CN 17 α -Hydroxypregn-4-ene-3,20-dione
CN 17 α -Hydroxyprogesterone
CN Gestageno
CN Gestageno Gador
CN Hydroxyprogesterone
CN NSC 15468
CN Pregn-4-en-17 α -ol-3,20-dione
CN Prodix
CN Prodox
CN U 3096
FS STEREOSEARCH
DR 67085-08-9
MF C21 H30 O3
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE,
HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT,
NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL,
VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4149 REFERENCES IN FILE CA (1907 TO DATE)
50 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

4154 REFERENCES IN FILE CAPLUS (1907 TO DATE)
26 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s 16-methylprogesterone/cn
L7 0 16-METHYLPOGESTERONE/CN

=> s 16-methylprogesterone/cn
L8 1 16-METHYLPROGESTERONE/CN

=> d

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 85027-24-3 REGISTRY
CN Pregn-4-ene-3,20-dione, 16-methyl- (7CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Progesterone, 16-methyl- (6CI)
OTHER NAMES:
CN 16-Methylprogesterone
FS STEREOSEARCH
MF C22 H32 O2
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, MEDLINE, RTECS*,
TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s cortexolone/cn
L9 1 CORTEXOLONE/CN

=> d

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 152-58-9 REGISTRY
CN Pregn-4-ene-3,20-dione, 17,21-dihydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Compound S (6CI)
OTHER NAMES:
CN Δ⁴-Pregnene-17α,21-diol-3,20-dione
CN 11-Deoxy-17-hydrocorticosterone
CN 11-Deoxy-17-hydroxycorticosterone
CN 11-Deoxycortisol
CN 11-Deoxycortisone
CN 11-Deoxyhydrocortisone
CN 11-Desoxy-17α-hydroxycorticosterone

CN 11-Desoxycortisol
 CN 11-Desoxyhydrocortisone
 CN 17,21-Dihydroxypregn-4-en-3,20-dione
 CN 17,21-Dihydroxypregn-4-ene-3,20-dione
 CN 17,21-Dihydroxyprogesterone
 CN 17-Hydroxy-11-deoxycorticosterone
 CN 17 α ,21-Dihydroxy-4-pregn-3,20-dione
 CN 17 α ,21-Dihydroxypregn-4-ene-3,20-dione
 CN 17 α ,21-Dihydroxyprogesterone
 CN 17 α -Hydroxycortexone
 CN 4-Pregnen-17 α ,21-diol-3,20-dione
 CN 4-Pregnene-17 α ,21-diol-3,20-dione
 CN **Cortexolone**
 CN Cortifen
 CN Cortisol, 11-deoxy-
 CN Cortodoxone
 CN NSC 18317
 CN Reichstein S
 CN Reichstein's compound S
 CN Reichstein's substance S
 CN SKF 3050
 CN Substance S
 FS STEREOSEARCH
 DR 478614-16-3, 37-60-5
 MF C21 H30 O4
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
 CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*,
 IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA,
 PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2256 REFERENCES IN FILE CA (1907 TO DATE)
 39 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2259 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> sel rn name 16
 E1 THROUGH E14 ASSIGNED

=> sel rn name 18
 E15 THROUGH E16 ASSIGNED

=> sel rn name 19
E17 THROUGH E47 ASSIGNED

=> FIL MEDL HCAPL BIOSIS USPATF
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
25.43	40.68

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 13:40:12 ON 17 MAR 2004

FILE 'HCAPLUS' ENTERED AT 13:40:12 ON 17 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:40:12 ON 17 MAR 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 13:40:12 ON 17 MAR 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s e1-14

L10 17849 ("Δ4-PREGNEN-17A-OL-3,20-DIONE"/BI OR "GESTAGENO GADOR"/BI OR GESTAGENO/BI OR HYDROXYPROGESTERONE/BI OR "NSC 15468"/BI OR "PREGN-4-EN-17A-OL-3,20-DIONE"/BI OR PRODIX/B I OR PRODOX/BI OR "U 3096"/BI OR "17A-HYDROXPREGN-4-ENE-3 ,20-DIONE"/BI OR 17A-HYDROXYPROGESTERONE/BI OR "17-HYDROXPREGN-4-ENE-3,20-DIONE"/BI OR 17-HYDROXYPROGESTERONE/BI OR 68-96 -2/BI)

=> s e15-16

L11 17 (16-METHYLPROGESTERONE/BI OR 85027-24-3/BI)

=> s e17-47

1 FILES SEARCHED...
2 FILES SEARCHED...
3 FILES SEARCHED...

L12 38817 ("Δ4-PREGNENE-17A,21-DIOL-3,20-DIONE"/BI OR "COMPOUND S"/BI OR CORTEXOLONE/BI OR CORTIFEN/BI OR "CORTISOL, 11-DEOXY-"/BI OR CORTODOXONE/BI OR "NSC 18317"/BI OR "REICHSTEIN S"/BI OR "REICHSTEIN'S COMPOUND S"/BI OR "REICHSTEIN'S SUBSTANCE S"/BI OR "SKF 3050"/BI OR "SUBSTANCE S"/BI OR 11-DEOXY-17-HYDROCORTICOSTERONE/BI OR 11-DEOXY-17-HYDROXYCORTICOSTERONE/BI OR 11-DEOXYCORTISOL/BI OR 11-DEOXYCORTISONE/BI OR 11-DEOXYHYDROCORTISONE/BI OR 11-DESOXY-17A-HYDROXYCORTICOSTERONE/BI OR 11-DESOXYCORTISOL/BI OR 11-DESOXYHYDROCORTISONE/BI OR 152-58-9/BI OR 17.ALPHA.-HYDROXYCORTEXONE/BI OR "17A,21-DIHYDROXY-4-PREGNEN-3,20-DIONE"/BI OR "17A,21-DIHYDROXPREGN-4-ENE-3,20-DIONE"/BI OR "17A,21-DIHYDROXYPROGESTERONE"/BI OR 17-HYDROXY-11-DEOXYCORTICOSTERONE/BI OR "17,21-DIHYDROXPREGN-4-EN-3,20-DIONE"/BI OR "17,21-DIHYDROXYPROGESTERONE"/BI OR "4-PREGNEN-17A,21-DIOL-3,20-DIONE"/BI OR "4-PREGNENE-17A,21-DIO

=>

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
36.90	77.58

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 13:57:41 ON 17 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 12, 2004 (20040312/UP).

FILE 'STNGUIDE' ENTERED AT 14:12:23 ON 17 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 12, 2004 (20040312/UP).

FILE 'MEDLINE' ENTERED AT 14:18:19 ON 17 MAR 2004

FILE 'HCAPLUS' ENTERED AT 14:18:19 ON 17 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:18:19 ON 17 MAR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'USPATFULL' ENTERED AT 14:18:19 ON 17 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s atheroscler? or arterioscler?
L13 174864 ATHEROSCLER? OR ARTERIOSCLER?

=> s 113 and 110; s 113 and 111; s 113 and 112
L14 391 L13 AND L10

L15 0 L13 AND L11

L16 2131 L13 AND L12

=> s 113 (S) 112
L17 64 L13 (S) L12

```
=> dup rem l17
PROCESSING COMPLETED FOR L17
L18      59 DUP REM L17 (5 DUPLICATES REMOVED)
```

=> d ibib abs 55-59

L18 ANSWER 55 OF 59 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 96002906 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7581821
TITLE: The inhibition of foam cell formation by sodium diethyldithiocarbamate.
AUTHOR: Schultz D; Skamarauskas J T; Law N; Mitchinson M J; Hunt J V
CORPORATE SOURCE: Department of Pathology, University of Cambridge, U.K.
SOURCE: Free radical research, (1995 Sep) 23 (3) 259-71.
Journal code: 9423872. ISSN: 1071-5762.

PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199512
ENTRY DATE: Entered STN: 19960124
Last Updated on STN: 19960124
Entered Medline: 19951207

AB A prominent feature of human atherosclerosis is the lipid-laden foamy macrophage, which often also contains the insoluble pigment, ceroid. The culture of macrophage-like cells, P388D1s, with artificial lipoproteins composed of cholestrylinoleate (CL) and bovine serum albumin (BSA) results in foam cell formation with lipoprotein uptake and the intracellular accumulation of ceroid. Ceroid accumulation is accompanied by the oxidation of the cholesterol ester as monitored by gas chromatography. The sodium salt of diethyldithiocarbamic acid (DDC) at 1-5 microM effectively inhibited lipoprotein uptake, cholestrylinoleate oxidation and ceroid accumulation in cultures of P388D1. Further studies showed that intracellular ceroid accumulation appeared to require the presence of cystine in the medium. Lipoprotein oxidation by this macrophage-like cell therefore appears to involve a mechanism dependent on cystine metabolism which is consistent with previous reports of macrophage-mediated lipoprotein oxidation. Studies on CL/BSA-induced ceroid accumulation in human monocytes also showed that DDC behaved in much the same manner. This inhibitory effect of DDC on foam cell formation, often considered a primary event of **atherosclerosis**, at concentrations as low as 1 microM, suggests the need for further, more comprehensive, studies on this compound's activities.

L18 ANSWER 56 OF 59 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 94313727 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8039270
TITLE: Vasoconstrictor responses to polymorphonuclear leucocytes from atherosclerotic rabbits.
AUTHOR: Sobey C G; Hart J L; Woodman O L
CORPORATE SOURCE: Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia.
SOURCE: Clinical and experimental pharmacology & physiology, (1994 Feb) 21 (2) 153-6.
Journal code: 0425076. ISSN: 0305-1870.
PUB. COUNTRY: Australia
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199408
ENTRY DATE: Entered STN: 19940905
Last Updated on STN: 19940905
Entered Medline: 19940822

AB 1. The vascular contractile effects of polymorphonuclear leucocytes (PMN) isolated from control rabbits and from rabbits made atherosclerotic by 1% cholesterol feeding for 8 weeks were examined. 2. Rings of control rabbit thoracic aorta with or without endothelium were mounted at 2 g tension in 10 mL organ baths and were submaximally contracted by phenylephrine (0.1 mumol/L). After 30 min incubation at 37 degrees C, the supernatant of PMN (5 x 10⁷/mL, in Tyrode solution containing 0.25% bovine serum albumin) was obtained by centrifugation for addition to the vascular preparation. 3. Control PMN supernatant (443 microL) caused contraction (0.58 +/- 0.15 g, n = 11) of phenylephrine-contracted aortic rings, which was prevented by removal of the endothelium (0.11 +/- 0.07 g, n = 5, P < 0.05). However, the control PMN supernatant had no contractile effect on aortic rings at resting tension (0.00 +/- 0.00 g, n = 8). 4. By comparison, atherosclerotic PMN supernatant (443 microL) caused a significantly greater contraction of the aortic rings (1.41 +/- 0.13 g, n = 9, P < 0.05 vs control PMN supernatant) that was only partly inhibited by removal of the endothelium (0.45 +/- 0.20 g, n = 9, P < 0.05). Moreover, PMN

supernatants from four of seven atherosclerotic rabbits contracted aortic rings at resting tension (3.5 +/- 1.4 g, n = 7). 5. These results suggest that the release of a stable vasoconstrictor substance(s) by PMN is enhanced under conditions of atherosclerosis
(ABSTRACT TRUNCATED AT 250 WORDS)

L18 ANSWER 57 OF 59 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 94261527 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8202444
TITLE: Atherosclerotic lesion development in hypercholesterolemic Japanese quail following probucol treatment: a biochemical and morphologic evaluation.
AUTHOR: Bocan T M; Mazur M J; Mueller S B; Charlton G; Kieft K A; Krause B R
CORPORATE SOURCE: Department of Atherosclerosis Research, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105.
SOURCE: Pharmacological research : official journal of the Italian Pharmacological Society, (1994 Jan-Feb) 29 (1) 65-76. Journal code: 8907422. ISSN: 1043-6618.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199407
ENTRY DATE: Entered STN: 19940714
Last Updated on STN: 19940714
Entered Medline: 19940707

AB Probucol, a cholesterol-lowering agent which possesses antioxidant properties, was evaluated in hypercholesterolemic Japanese quail in order to assess the significance of antioxidant therapy on the development of atherosclerosis. Forty quail were fed a 0.5% cholesterol diet containing 0, 100, 200 or 500 mg kg⁻¹ probucol for 2 months. At necropsy, plasma total and lipoprotein cholesterol and lipoprotein distribution were unchanged despite plasma probucol levels of 50 to 59 micrograms ml⁻¹. The cholestryl ester content of the liver and blood vasculature (brachiocephalic artery and aortic arch combined) was reduced by 33% and 62%, respectively, in animals given 500 mg kg⁻¹ probucol. The vascular free cholesterol content was also reduced by 43 to 60% over the probucol dose range. Morphometric analysis of the brachiocephalic artery revealed that probucol reduced the incidence of lesions containing esterase-positive cells from 62% in untreated animals to 26% and 13% in animals administered 200 and 500 mg kg⁻¹ probucol, respectively. No difference in mean wall thickness or area of the brachiocephalic artery was noted between the groups. Thus, we conclude that probucol can blunt the cholestryl ester and macrophage enrichment of atherosclerotic lesions and this activity appears to be mediated by the compound's antioxidant properties since the changes noted were seen in the absence of alterations in plasma total and lipoprotein cholesterol levels.

L18 ANSWER 58 OF 59 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1978:421576 HCAPLUS
DOCUMENT NUMBER: 89:21576
TITLE: Effect of the blockade of β -hydroxylase II in the adrenal cortex on blood lipoproteins in rabbits with experimental atherosclerosis
AUTHOR(S): Livshits, I. B.; Sherstyuk, G. V.; Bestuzheva, S. V.
CORPORATE SOURCE: Beloruss. Inst. Usovershenstvovaniya Vrachei, Minsk, USSR
SOURCE: Mater. Biokhim. Konf. Pribalt. Resp. B. SSR, 5th (1976), Volume 1, 150-2. Editor(s): Sibul, I. K. Akad. Nauk Est. SSR: Tallinn, USSR.
CODEN: 38BKAW
DOCUMENT TYPE: Conference

LANGUAGE: Russian
AB In rabbits with cholesterol-induced atherosclerosis, the plasma levels of cortisol, corticosterone, cortexolone, α -lipoproteins, pre β -lipoproteins, β -lipoproteins, and chylomicrons increased 2-fold, decreased by factors 2 and 3, increased 2- and 15-fold, and decreased by factors 1.5 and 1.5, resp., as compared with those of normal rabbits. After the blocking of β -hydroxylase II in adrenal cortex with i.v. injection of 15 mg metapyrone/kg body weight The corresponding levels increased 4-fold, decreased by factors 1.2 and 4, and increased 4-, 2.5-, 2-, and 2.5-fold, resp., as compared with those of normal rabbits after the metapyrone injection. Mechanism of the changes is discussed.

L18 ANSWER 59 OF 59 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1968:85639 HCAPLUS

DOCUMENT NUMBER: 68:85639

TITLE: Biosynthesis of glucocorticoids by adrenal glands of dogs with experimental atherosclerosis

AUTHOR(S): Tsiomik, V. A.; Goncharova, D. N.; Kuz'minskii, N. P.

SOURCE: Giperzonicheskaya Bolezn, Ateroskler. Koronarnaya Nedostatochnost (1967), 178-83

CODEN: 19XRAC

DOCUMENT TYPE: Conference

LANGUAGE: Russian

AB In adrenals of dogs with exptl. atherosclerosis, the biosynthesis of all glucocorticoids was markedly decreased in comparison with the tissue of normal ones. The synthesis of hydrocortisone was decreased from 253.1 to 108.5 μ g./g., the synthesis of corticosterone from 157.9 to 112.5 \pm 7.2 μ g./g., and that of cortisone from 28 to 12 μ g./g. The amount of 11-deoxy-17-hydroxycorticosterone, the precursor of hydrocortisone, was increased from 28.2 to 56.1 μ g./g. The decrease of biosynthesis of the main glucocorticoids and the accumulation of the precursor were explained as a result of decreased activities of the resp. enzymes (11β -hydroxylase, 21β -hydroxylase, 3β -hydroxylase). In addition to it, the detailed histol. and histochem. anal. of adrenal tissue from atherosclerotic animals revealed a number of changes which are apparently in causal connection with atherogenesis. The total weight of adrenals was 1.5-2-fold higher in comparison with adrenals of normal animals. It was caused by hyperplasia and hypertrophy of cellular elements of zona fasciculata and reticularis. In many of these cells, however, necrobiotic and necrotic changes were found. Islets of these cells were surrounded by connective tissue derived from capsule. The cells of both zones were rich in ribonucleoproteins, Schiff-pos. compds., acid mucopolysaccharides, and lipids. In several cases the decrease of cellular cholesterol was found. On the other hand, the zona glomerulosa was relatively narrow, irregular, and the cells were smaller and poor in lipids. In adrenal cortex of atherosclerotic animals small adenomas with distinct capsules were present. The function of adrenal cortex is impaired in atherosclerosis.

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY SESSION

FULL ESTIMATED COST

10.68

90.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-1.39

-1.39

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 14:20:35 ON 17 MAR 2004

Connecting via Winsock to STN